The analysis has also demonstrated that the vaccine could generate a T-cell response.

There happens to be no remedy for Herpes Simplex 2 infection.. Admedus’ HSV-2 therapeutic vaccine achieves primary endpoint in Phase 1 trial Admedus today announced that interim research results on its Phase 1 trial of a therapeutic vaccine for Herpes Simplex Virus have shown that it achieved the primary endpoint of the study when you are safe in the analysis subjects. In addition, the analysis has also demonstrated that the vaccine could generate a T-cell response. In December 2013 and further analysis of the info in still ongoing The dosing of study topics was completed.Progression-free of charge survival as assessed by the investigator and general survival were analyzed with the same strategies as those used for the analysis of independently assessed progression-free survival. Adverse events had been evaluated descriptively in the safety population . Results Study People Through the period from February 2008 through July 2010, a total of 808 patients had been enrolled at 204 centers in 25 countries; 406 were randomly designated to placebo plus trastuzumab plus docetaxel , and 402 to pertuzumab plus trastuzumab plus docetaxel . The cutoff time for collection of data was May 13, 2011. The baseline characteristics of the individuals were similar in the two groups .